Find Ralmitaront manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

ACTIVE PHARMA INGREDIENTS

0

API Suppliers

0

USDMF

0

CEP/COS

0

JDMF

0

EU WC

0

KDMF

0

NDC API

0

VMF

0

Listed Suppliers

0INTERMEDIATES

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

FINISHED DOSAGE FORMULATIONS

0

FDF Dossiers

0

FDA Orange Book

0

Europe

0

Canada

0

Australia

0

South Africa

0

Listed Dossiers

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

PATENTS & EXCLUSIVITIES

0

US Patents

0

US Exclusivities

0

Health Canada Patents

GLOBAL SALES INFORMATION

US Medicaid

NA

Annual Reports

NA

Regulatory FDF Prices

NA

MARKET PLACE

0

API

0

FDF

DIGITAL CONTENT

0

Data Compilation #PharmaFlow

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

0

News #PharmaBuzz

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: 2133417-13-5, Ralmitaront [inn], Ralmitaront [usan], Rg7906, Qa8mw1q80p, Ro6889450
Molecular Formula
C17H22N4O2
Molecular Weight
314.4  g/mol
InChI Key
XHHXGKRFUPEPFM-OAHLLOKOSA-N
FDA UNII
QA8MW1Q80P

Ralmitaront
Ralmitaront is under investigation in clinical trial NCT04512066 (A Trial of the Efficacy and the Safety of RO6889450 (Ralmitaront) vs Placebo in Patients With an Acute Exacerbation of Schizophrenia or Schizoaffective Disorder).
1 2D Structure

Ralmitaront

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
5-ethyl-4-methyl-N-[4-[(2S)-morpholin-2-yl]phenyl]-1H-pyrazole-3-carboxamide
2.1.2 InChI
InChI=1S/C17H22N4O2/c1-3-14-11(2)16(21-20-14)17(22)19-13-6-4-12(5-7-13)15-10-18-8-9-23-15/h4-7,15,18H,3,8-10H2,1-2H3,(H,19,22)(H,20,21)/t15-/m1/s1
2.1.3 InChI Key
XHHXGKRFUPEPFM-OAHLLOKOSA-N
2.2 Other Identifiers
2.2.1 UNII
QA8MW1Q80P
2.3 Synonyms
2.3.1 Depositor-Supplied Synonyms

1. 2133417-13-5

2. Ralmitaront [inn]

3. Ralmitaront [usan]

4. Rg7906

5. Qa8mw1q80p

6. Ro6889450

7. Rg-7906

8. Ro-6889450

9. Ralmitaront [who-dd]

10. 5-ethyl-4-methyl-n-[4-[(2s)-morpholin-2-yl]phenyl]-1h-pyrazole-3-carboxamide

11. Dtxsid901336976

12. 1h-pyrazole-3-carboxamide, 5-ethyl-4-methyl-n-(4-(2s)-2-morpholinylphenyl)-

13. Example 1 [wo2017157873a1]

14. 5-ethyl-4-methyl-n-{4-[(2s)-morpholin-2-yl]phenyl}-1h-pyrazole-3-carboxamide

15. Example 1 (wo2017157873a1)

16. 5-ethyl-4-methyl-n-(4-((2s)-morpholin-2-yl)phenyl)-1h-pyrazole-3-carboxamide

17. Refchem:875106

18. Dtxcid501767288

19. Ralmitaront [usan:inn]

20. Unii-qa8mw1q80p

21. (s)-5-ethyl-4-methyl-n-(4-(morpholin-2-yl)phenyl)-1h-pyrazole-3-carboxamide

22. Who 11130

23. 5-ethyl-4-methyl-~{n}-[4-[(2~{s})-morpholin-2-yl]phenyl]-1~{h}-pyrazole-3-carboxamide

24. Ralmitaront (usan/inn)

25. Orb1298302

26. Chembl4594376

27. Schembl19356836

28. Gtpl12190

29. Ex-a5232

30. Akos040759709

31. Da-67109

32. Ms-24620

33. Hy-109157

34. Cs-0116071

35. D11830

36. G17835

37. 5-ethyl-4-methyl-n-[4-(2s)-2-morpholinylphenyl]-1h-pyrazole-3-carboxamide

38. Uju

2.4 Create Date
2017-10-07
3 Chemical and Physical Properties
Molecular Weight 314.4 g/mol
Molecular Formula C17H22N4O2
XLogP31.6
Hydrogen Bond Donor Count3
Hydrogen Bond Acceptor Count4
Rotatable Bond Count4
Exact Mass Da
Monoisotopic Mass Da
Topological Polar Surface Area79
Heavy Atom Count23
Formal Charge0
Complexity398
Isotope Atom Count0
Defined Atom Stereocenter Count1
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty